Researchers at Mount Sinai and Memorial Sloan Kettering believe they’ve made a breakthrough in a new form of cancer treatment ...

Eligibility for treatment with the latest cancer drugs is often determined by genetic mutations in tumors, criteria that ...

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ...

A collaborative effort between Mount Sinai and Memorial Sloan Kettering Cancer Center has shed valuable light on how ...

Research suggests the benefits of testosterone therapy after prostate cancer surgery in select men may outweigh risks.

Researchers at The Tisch Cancer Institute at Mount Sinai, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), ...

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will ...

The age of testing for colorectal cancer has been pushed from 50 to 45, and it is even earlier for at-risk patients because of the rise in the number of young adults being diagnosed with the disease.

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors - a type of immunotherapy - ...